SCHEMBL23250757

SCHEMBL23250757

O=c1c(O)ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DBH P09172 2/20 0.46
▸ MMP2 P08253 1/20 0.46
▸ MAPT P10636 4/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ ALOX15 P16050 3/20 0.45
▸ POLB P06746 3/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ APEX1 P27695 2/20 0.45
▸ RECQL P46063 2/20 0.45
▸ BLM P54132 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ GMNN O75496 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL122963 0.80 ALDH1A1 (0.60) DBHMMP2MAPTALDH1A1ALOX15
SCHEMBL29745810 0.77 — —
SCHEMBL78212 0.77 — —
Formaldehyde SCHEMBL18941460 0.76 ALDH1A1 (0.47) DBHMMP2MAPTALDH1A1ALOX15
SCHEMBL28328921 0.75 — —
Hydrogen Sulfide SCHEMBL28150137 0.75 — —
Hydrochloric Acid SCHEMBL6006296 0.75 — —
SCHEMBL27495414 0.75 — —
SCHEMBL22493842 0.75 — —
Hydrochloric Acid SCHEMBL16337918 0.75 ALDH1A1 (0.53) DBHMMP2MAPTALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073131-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) 2024-04-04 — — WO disclosed
US-20230406803-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Kinesid Therapeutics, Inc (US) 2023-12-21 — — US disclosed
EP-4045477-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 — — EP disclosed
WO-2021076938-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed
WO-2021076938-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406803-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TFRC, SDHB DBH 277/4885MMP2 3444/4885MAPT 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback